Evidence map›Paper›PMID 34200197›Full record

ArticlePharmaceutics2021

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody

Yongsheng Liu, Anzhelika Vorobyeva, Tianqi Xu, Anna Orlova, Annika Loftenius, Theresa Bengtsson, Per Jonasson, Vladimir Tolmachev, Fredrik Y Frejd

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Evaluation of a novelEuropean journal of nuclear medicine and molecular imaging · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Yongsheng LiuDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0001-5871-5779
Anzhelika VorobyevaDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-4778-3909
Tianqi XuDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-1826-4093
Anna OrlovaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.ORCID 0000-0001-6120-2683
Annika LofteniusAffibody AB, 171 65 Solna, Sweden.
Theresa BengtssonAffibody AB, 171 65 Solna, Sweden.
Per JonassonAffibody AB, 171 65 Solna, Sweden.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-6122-1734
Fredrik Y FrejdDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Uppsala University · SEAffibody (Sweden) · SE

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2019-1925
6 · The paper itself

Abstract

Radiolabeled Affibody-based targeting agent

Indexed as

177Luaffibody moleculealbumin binding domain (ABD)biodistributionDOTAradionuclide therapyscaffold proteinSKOV-3 xenograft

Identifiers

PMID34200197
PMCPMC8226825
OpenAlexW3166935560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.